Erythropoietin enhances immunostimulatory properties of immature dendritic cells

Clinical and Experimental Immunology

Volumn 165, Issue 2, 2011, Pages 202-210

  Rocchetta, F ^a   Solini, S ^a   Mister, M ^a   Mele, C ^a   Cassis, P ^a   Noris, M ^a   Remuzzi, G ^b   Aiello, S ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Dendritic cell; Erythropoietin; TLR 4

Indexed keywords

CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 23; LIPOPOLYSACCHARIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROTECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD40; ANTIGENS, CD86; BLOTTING, WESTERN; BONE MARROW CELLS; CELL DIFFERENTIATION; DENDRITIC CELLS; ERYTHROPOIETIN; IMMUNOLOGIC FACTORS; INTERLEUKIN-12; INTERLEUKIN-23; LIPOPOLYSACCHARIDES; POLYMERASE CHAIN REACTION; RATS; RATS, INBRED BN; RECEPTORS, CCR7; RECEPTORS, ERYTHROPOIETIN; TOLL-LIKE RECEPTOR 4;

EID: 79960063030     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04417.x     Document Type: Article

References (24)

1. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol 2008; 36:1573-84.
2. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141:14-31.
3. Sasaki R. Pleiotropic functions of erythropoietin. Intern Med 2003; 42:142-9.
4. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006; 70:246-50.
5. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008; 264:405-32.
6. Yuan R, Maeda Y, Li W, Lu W, Cook S, Dowling P. Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS ONE 2008; 3:e1924.
7. Prutchi Sagiv S, Lifshitz L, Orkin R, Mittelman M, Neumann D. Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator? Exp Hematol 2008; 36:1682-90.
8. Lifshitz L, Prutchi-Sagiv S, Avneon M, Gassmann M, Mittelman M, Neumann D. Non-erythroid activities of erythropoietin: functional effects on murine dendritic cells. Mol Immunol 2009; 46:713-21.
9. Cassis P, Solini S, Azzollini N etal. Erythropoietin (EPO) and a non-erythropoietic carbamylated derivative (CEPO) protect the kidney graft from ischemia/reperfusion injury. Am J Transpl 2009; 9 (Suppl. 2):492.
10. - cells with tolerogenic properties. Transplantation 2007; 83:474-84.
11. Elliott S, Busse L, Bass MB etal. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107:1892-5.
12. Duez C, Gosset P, Tonnel AB. Dendritic cells and toll-like receptors in allergy and asthma. Eur J Dermatol 2006; 16:12-16.
13. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006; 26:430-7.
14. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
15. Lopez-Bravo M, Ardavin C. In vivo induction of immune responses to pathogens by conventional dendritic cells. Immunity 2008; 29:343-51.
16. Pulendran B, Tang H, Denning TL. Division of labor, plasticity, and crosstalk between dendritic cell subsets. Curr Opin Immunol 2008; 20:61-7.
17. Gottfried E, Kreutz M, Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev 2008; 19:65-77.
18. Prutchi-Sagiv S, Golishevsky N, Oster HS etal. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? Br J Haematol 2006; 135:660-72.
19. Ozawa T, Kato K, Toba K etal. Serum erythropoietin level as a marker of limb ischemia. Int J Cardiol 2008; 130:106-8.
20. Jin DK, Shido K, Kopp HG. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12:557-67.
21. Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol 2009; 130:41-50.
22. Jiang S, Herrera O, Lechler RI. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol 2004; 16:550-7.
23. Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev 2003; 196:125-46.
24. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301-5.